Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-01-01

Study Completion Date

2026-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints, which are important for the patient such as overall survival and side effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer

NCT05758948

Metastatic Breast Cancer

UNKNOWN

Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal

NCT05530759

Hematopoietic and Lymphoid System Neoplasm Metastatic Malignant Solid Neoplasm

RECRUITING

The Head and Neck Tumor Biobank

NCT01644786

Head and Neck Squamous Cell Carcinoma

COMPLETED

Biomarker Development for Response Prediction by DNA Mutational Analysis

NCT01855061

Neoplasm Metastasis

TERMINATED

Genetic Characteristics of Metastatic Breast Cancer Patients

NCT04258735

Metastatic Breast Cancer

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It has already been known for a long time that cancer is a genetic disorder and that the development of the illness is a very complex interaction between genetic and surrounding factors. Also the response on therapy and the development and seriousness of side effects is stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it is not only the DNA that plays an important role but also the systems of control at protein level. At this moment a lot of questions remain to be answered because up till now the studies were of rather restricted statistic strength with frequently inconsistent dates and moreover retrospective. Major retrospective studies are necessary to distinguish the relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and toxicity in which an as broad as possible patient group is being monitored. For this reason we want to take blood samples in MAASTRO clinic of all patients with lung cancer and to store it encrypted so that we can perform DNA and protein analyses in future and to correlate the results with survival and toxicity of the treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* cancer

Exclusion Criteria

* not able to comply with follow-up

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dirk De Ruysscher, Prof PHD

Role: PRINCIPAL_INVESTIGATOR

CCMO

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Maastricht Radiation Oncology

Maastricht, Limburg, Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Philippe Lambin, Prof PHD

Role: CONTACT

[email protected]

31 (0) 088 44 55 666

Dirk De Ruysscher, Prof PHD

Role: CONTACT

[email protected]

31 (0) 088 44 55 666

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dirk De Ruysscher, Prof PHD

Role: primary

[email protected]

31 (0) 88 44 55 666

Philippe Lambin, Prof PHD

Role: backup

[email protected]

31 (0) 88 44 55 666

References

Explore related publications, articles, or registry entries linked to this study.

Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, van der Weide H, Rao B, Lambin P. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):360-8. doi: 10.1016/j.ijrobp.2010.06.011. Epub 2010 Oct 1.

Reference Type DERIVED

PMID: 20888135 (View on PubMed)

Identifier Type: -

Identifier Source: nct_alias

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.

NCT00974610 COMPLETED

Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

NCT02470819 WITHDRAWN NA

Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer

NCT00898781 TERMINATED

The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.

NCT06765850 RECRUITING

Collecting and Storing Blood Samples From Patients With Cancer

NCT00900120 WITHDRAWN

Prognostic Factors for All Types of Cancer Combined

NCT00704587 COMPLETED

Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance

NCT00026663 COMPLETED

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

NCT05539677 RECRUITING

DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer

NCT00899548 COMPLETED

A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer

NCT01919749 COMPLETED NA

Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

NCT00896675 COMPLETED

Collection of Blood, Bone Marrow, Tumor or Tissue Samples

NCT00043615 COMPLETED

Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors

NCT02215928 RECRUITING

Analysis of Circulating Tumor Markers in Blood

NCT04025541 RECRUITING NA

Culture of Circulating Tumor Cells Isolated From Cancer Patients With Metastatic Disease

NCT02781025 COMPLETED

Feasibility Study of a Molecular Karyotype Using a Very High-throughput Sequencing Approach, the "Massive Parallel Sequencing" on Circulating Tumor DNA

NCT04104633 COMPLETED NA

Characterization & Comparison of Drugable Mutations in Primary and Metastatic Tumors, CTCs and cfDNA in MBCpatients

NCT02626039 COMPLETED

Biology Studies of Hematologic Cancers

NCT00923442 ENROLLING_BY_INVITATION

Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies

NCT03762733 ENROLLING_BY_INVITATION

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

NCT00242723 RECRUITING

S8600-S9031-S9333-A, Study of DNA in Samples From Patients With Acute Myeloid Leukemia

NCT01434329 COMPLETED

Tumor Phenotypes and Correlation to Clinical Outcomes in Cancer

NCT00283530 TERMINATED

Research Into Biomarkers Predictive of Survival and Response to Cancer Treatment

NCT06851975 RECRUITING NA

Detection of Tumor DNA in Blood Samples From Cancer Patients

NCT02288754 UNKNOWN

NSABP Patient Registry and Biospecimen Profiling Repository

NCT01793805 COMPLETED

Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer

Study Results

Basic Information

Brief Summary

Related Clinical Trials

Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer

Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal

The Head and Neck Tumor Biobank

Biomarker Development for Response Prediction by DNA Mutational Analysis

Genetic Characteristics of Metastatic Breast Cancer Patients

Detailed Description

Conditions

Study Design

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Maastricht University Medical Center

Maastricht Radiation Oncology

Responsible Party

Principal Investigators

Dirk De Ruysscher, Prof PHD

Locations

Maastricht Radiation Oncology

Countries

Central Contacts

Philippe Lambin, Prof PHD

Dirk De Ruysscher, Prof PHD

Facility Contacts

Dirk De Ruysscher, Prof PHD

Philippe Lambin, Prof PHD

References

Other Identifiers

08-06-23/01

NCT00157352

NCT00157365

NCT00157391

NCT00157404

NCT00157417

NCT00157430

NCT00157443

NCT00157456

NCT00157469

NCT00157495

NCT00181337

NCT00181376

NCT00181389

NCT00181402

NCT00181415

NCT00181428

NCT00181441

NCT00181454

NCT00181467

NCT00181480

NCT00181493

NCT00181519

NCT01067872

More Related Trials